Trial Profile
A phase II trial of trastuzumab plus weekly ixabepilone (BMS-247550) and carboplatin in patients with HER/neu-positive metastatic breast cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Ixabepilone (Primary) ; Trastuzumab (Primary) ; Carboplatin
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- 01 Apr 2011 Additional lead trial centres identified as reported by ClinicalTrials.gov.
- 01 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Jul 2006 Status change